Withuspharmaceutical Co.Ltd (330350) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Withuspharmaceutical Co.Ltd stock KRW 8,279, price KRW 6,560, upside +26.2%, quality 61 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 5,528 KRW – 15,251 KRW · fair‑value band 5,328 KRW – 10,348 KRW · the 6,560 KRW price screens below the 8,279 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Withuspharmaceutical Co.Ltd in your weekly email
Every Wednesday you see whether Withuspharmaceutical Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea.
Show moreShow less
It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitourinary tract medications, psychotropic agents, and other products.
The company was previously known as Withers Medipharm Co. , Ltd. and changed its name to WITHUS PHARMACEUTICAL Co.,LTD. in October 2007. WITHUS PHARMACEUTICAL Co.,LTD. was founded in 2004 and is headquartered in Seoul, South Korea.
Stock analysis
Withuspharmaceutical Co.Ltd (330350) currently trades at 6,560 KRW, while our model-based Fair Value estimate is 8,279 KRW, implying the stock looks roughly 21% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 9,157 KRW per share, and 15 of the 26 models we run sit above the 6,560 KRW price.
Bear case: the Dividend Discount group reads lowest at 1,184 KRW, and 11 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 5,328 KRW (bear) to 10,348 KRW (bull), the price of 6,560 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Withuspharmaceutical Co.Ltd reported revenue of 106B KRW in FY2025 versus 57.4B KRW in FY2021, a compound +16.7%/yr. Reported net income was 5.0B KRW in FY2025, compounding +3.9%/yr from FY2021.
Key figures
Market cap 86.6B KRW (≈ $64.0M) Micro · P/E ratio 10.8 · P/S ratio 0.78 · EPS (TTM) 603.38 KRW · Dividend yield 1.6% · Net margin 7.1% · Return on equity 8.0% · Return on assets (EBIT) 4.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 26%, 330350 screens cheaper than that median.
Fair Value models
Bear5,328 KRWFair Value 8,279 KRWBull10,348 KRW
Price 6,560 KRW · Upside +26.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (517.42 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+3.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +4.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +3.1%
Dividend (yield on the price)1.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 5%
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 323 per share, median 738 in 2017 to 2018). It measures the recovery from the trough, not lasting growth.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +16.5% a year for the price.
Compare Withuspharmaceutical Co.Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside+26.2% · Top 25%
Profitability
Return on equity (12 months)8.0% · Above median
Return on assets3.6% · Below median
Net margin (12 months)7.1% · Below median
Operating margin (12 months)3.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)10.8% · Above median
Dividend yield (12 months)1.6% · Below median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)10.8× · Cheapest 25%
P/B0.88× · Cheapest 25%
P/S (12 months)0.78× · Cheapest 25%
Price / free cash flow (fiscal year)23.6× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Withuspharmaceutical Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/330350
Frequently asked questions
Is Withuspharmaceutical Co.Ltd (330350) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 8,279 KRW versus a price of 6,560 KRW, about +26% upside (undervalued).
What is the fair value of 330350?
Our model-based fair value for Withuspharmaceutical Co.Ltd is 8,279 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 6,560 KRW.
What is the quality score of 330350?
Withuspharmaceutical Co.Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Withuspharmaceutical Co.Ltd (330350)?
Our model-based price target is the fair value of 8,279 KRW (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 5,328 KRW, optimistic scenario 10,348 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Withuspharmaceutical Co.Ltd stock forecast for 2026?
Our models put fair value at 8,279 KRW, about +26% upside versus a price of 6,560 KRW (undervalued). Cautious scenario 5,328 KRW, optimistic scenario 10,348 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Withuspharmaceutical Co.Ltd (330350)?
Withuspharmaceutical Co.Ltd reported trailing-twelve-month revenue of about 112B KRW (latest available figure, as of Nov 9, 2026).
Does Withuspharmaceutical Co.Ltd pay a dividend?
Withuspharmaceutical Co.Ltd currently shows a dividend yield of 1.55% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Withuspharmaceutical Co.Ltd (330350)?
Withuspharmaceutical Co.Ltd has a dividend yield of 1.6%.
What growth is priced into Withuspharmaceutical Co.Ltd (330350)?
For today's price to be fair in a discounted-cash-flow model, Withuspharmaceutical Co.Ltd would have to grow free cash flow by +18.9 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +32.4 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 330350 use?
Our models discount Withuspharmaceutical Co.Ltd at 12.1 %: a base by market capitalisation (micro), damped by beta 0.68, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Withuspharmaceutical Co.Ltd that is +18.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Withuspharmaceutical Co.Ltd (330350) delivered so far?
Over the past 5 years revenue at Withuspharmaceutical Co.Ltd grew +32.4 % a year. The price currently implies free-cash-flow growth of +18.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Withuspharmaceutical Co.Ltd (330350) growing?
The median revenue growth in the sector is +14.3 % a year. That is the yardstick for the growth priced into Withuspharmaceutical Co.Ltd (+18.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Withuspharmaceutical Co.Ltd (330350)?
The free-cash-flow yield on the price is 4.23 %: that much free cash flow Withuspharmaceutical Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Withuspharmaceutical Co.Ltd (330350)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Withuspharmaceutical Co.Ltd it is 8,279 KRW per share (as of Nov 9, 2026), against a price of 6,560 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Withuspharmaceutical Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 330350 trades below its calculated fair value: price 6,560 KRW, fair value 8,279 KRW, a gap of about +26% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 330350?
No. The price is what the market pays today (6,560 KRW); the fair value is what the company's own numbers justify (8,279 KRW). For Withuspharmaceutical Co.Ltd the two are 1,719 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Withuspharmaceutical Co.Ltd worth?
The market values Withuspharmaceutical Co.Ltd at about 86.6B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 6,560 KRW; our models calculate a fair value of 8,279 KRW per share.
What do the bullish and bearish scenarios say about 330350?
Our models span a range for Withuspharmaceutical Co.Ltd: cautious scenario 5,328 KRW, base 8,279 KRW, optimistic 10,348 KRW per share (as of Nov 9, 2026, price 6,560 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 330350?
Withuspharmaceutical Co.Ltd trades at a price-to-earnings ratio of 10.8 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 8,279 KRW is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings: 22.9. Other multiples: P/B 0.9, P/S 0.8, EV/EBITDA 8.6.
How solid is the balance sheet of Withuspharmaceutical Co.Ltd (330350)?
Balance-sheet figures for Withuspharmaceutical Co.Ltd (as of Nov 9, 2026): return on equity 8.0%, debt of 0.02 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 330350 from its 52-week high?
Withuspharmaceutical Co.Ltd trades at 6,560 KRW, about 45% below its 52-week high of 11,940 KRW and 9% above the low of 6,010 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 8,279 KRW is for.
Which stocks are comparable to Withuspharmaceutical Co.Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Withuspharmaceutical Co.Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 6,560 KRW, calculated fair value 8,279 KRW (+26%), Quality Score 61/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 330350 calculated?
We run Withuspharmaceutical Co.Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 8,279 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Withuspharmaceutical Co.Ltd currently trades 21% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Withuspharmaceutical Co.Ltd (330350)?
The closing price on Nov 9, 2026 was 6,560 KRW. Our model-based fair value is 8,279 KRW, about +26% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Withuspharmaceutical Co.Ltd right now?
Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (5,328 KRW to 10,348 KRW) leaves room in how you read the outcome.
Key figures of Withuspharmaceutical Co.Ltd
How large is the market capitalisation of Withuspharmaceutical Co.Ltd (330350)?
The market capitalisation of Withuspharmaceutical Co.Ltd is 86.6B KRW (≈ $64.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Withuspharmaceutical Co.Ltd (330350)?
The price-to-sales ratio of Withuspharmaceutical Co.Ltd is 0.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Withuspharmaceutical Co.Ltd (330350)?
Earnings per share at Withuspharmaceutical Co.Ltd are 603.38 KRW (price ÷ EPS = P/E 10.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Withuspharmaceutical Co.Ltd (330350)?
The dividend yield of Withuspharmaceutical Co.Ltd is 1.6% (payout 16.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Withuspharmaceutical Co.Ltd (330350)?
The net margin of Withuspharmaceutical Co.Ltd is 7.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Withuspharmaceutical Co.Ltd (330350)?
The return on equity (ROE) of Withuspharmaceutical Co.Ltd is 8.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Withuspharmaceutical Co.Ltd (330350)?
On an EBIT basis the return on assets of Withuspharmaceutical Co.Ltd is 4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Withuspharmaceutical Co.Ltd (330350)?
The operating margin of Withuspharmaceutical Co.Ltd is 3.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Withuspharmaceutical Co.Ltd (330350)?
Revenue at Withuspharmaceutical Co.Ltd is growing +10.8% versus a year earlier (3y avg +18.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Withuspharmaceutical Co.Ltd (330350)?
Earnings per share at Withuspharmaceutical Co.Ltd are growing +52.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Withuspharmaceutical Co.Ltd (330350) carry?
The net debt of Withuspharmaceutical Co.Ltd is 944M KRW (fiscal year 2025, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Withuspharmaceutical Co.Ltd in the live analysis
One click puts Withuspharmaceutical Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026